DEUTSCHE-POST-DHL-GROUP
7.7.2021 15:49:07 CEST | Business Wire | Press release
Deutsche Post DHL Group (Symbol: DPW), the world’s leading logistics company, has today released preliminary results for the second quarter of 2021. Simultaneously, the outlook for the current financial year and for 2023 has been raised. Furthermore, an one-time corona bonus1 for approximately 550,000 employees worldwide has been decided. Preliminary operating profit (EBIT) for the second quarter has improved to record level with around EUR 2,075 million (Q2 2020: EUR 912 million) and has more than doubled compared to previous year. Against the backdrop of the excellent business performance, the Group has raised its EBIT outlook for 2021 to more than EUR 7.0 billion (so far: more than EUR 6.7 billion). The mid-term EBIT outlook for 2023 is now expected to be more than EUR 7.4 billion (so far: more than EUR 7.0 billion).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210707005615/en/
“The second quarter proved once again that global trade volume continues to recover and the e-commerce boom is sustainable – and we benefit strongly from both. All divisions continue to operate at full speed worldwide and achieve double-digit EBIT growth rates. We want to thank our employees who do fantastic work around the world and deserve another corona bonus“, said Frank Appel, CEO of Deutsche Post DHL Group.
Group grants once again one-time corona bonus of around EUR 200 million
As an appreciation for their tireless efforts during the pandemic the Group has decided to grant again a corona bonus of EUR 3002 to employees worldwide. This one-time payment is aimed at approximately 550,000 colleagues in all divisions and countries. Excluded are Executives. The corresponding expenses of around EUR 200 million will be booked in the third quarter 2021 and are already included in the updated earnings outlook for 2021.
All divisions achieved a significant jump in earnings
All divisions significantly exceeded the previous year's results. Network capacity utilization was constantly high in the second quarter 2021. B2C shipment volumes remained ahead of last year in all networks, while the recovery in the B2B businesses continued to gain momentum. At the same time the tight capacity situation both in Ocean and Air Freight markets remained unchanged.
Express: EBIT in the Express division reached around EUR 1,170 million in the second quarter 2021 compared to EUR 565 million in the previous year’s quarter.
Global Forwarding, Freight: EBIT in Global Forwarding, Freight stood at around EUR 315 million in the second quarter 2021, also clearly ahead of previous year’s result of EUR 190 million.
Supply Chain: EBIT at Supply Chain came in at around EUR 195 million in the second quarter 2021. It was at EUR 33 million in Q2 2020 in the initial stage of the pandemic.
eCommerce Solutions: eCommerce Solutions recorded EBIT of around EUR 115 million in the second quarter 2021, significantly above last year’s Q2 result which stood at EUR 1 million.
Post & Parcel Germany: EBIT in Post & Parcel Germany in the second quarter 2021 was around EUR 315 million (Q2 2020: EUR 264 million).
The positive business development is underpinned by a continued strong development of cash flow. Free cash flow in the second quarter 2021 amounted to more than EUR 800 million (Q2 2020: EUR 605 million). For the first half of 2021 free cash flow now stands at more than EUR 2.0 billion (H1 2020: EUR 196 million).
Earnings outlook raised in expectation of unchanged high shipment volumes and improved efficiency
In light of the ongoing earnings momentum the Group EBIT for 2021 is now expected to be more than EUR 7.0 billion (so far: more than EUR 6.7 billion). This includes additional expenses of around EUR 200 million for the one-time corona bonus. For the full year 2021, the Group now forecasts a free cash flow of more than EUR 3.2 billion (so far: more than EUR 3.0 billion). Gross capex in 2021 is expected to reach around EUR 3.9 billion (so far: around EUR 3.8 billion). The full year 2021 Group tax rate will now reach 28 percent, the upper end of the previously guided range of 26-28 percent.
Mid-term guidance for Group EBIT 2023 is now expected to be more than EUR 7.4 billion (previously: more than EUR 7.0 billion). The aggregated 2021-2023 guidance for free cash flow was left unchanged at around EUR 9.0 billion. The cumulative outlook for gross capex was also confirmed at around EUR 11.0 billion for the period 2021 to 2023.
The comprehensive disclosure for Q2/H1 2021 will be published as planned on August 5, 2021.
– End –
Deutsche Post DHL Group Deutsche Post DHL Group is the world’s leading logistics company. The Group connects people and markets and is an enabler of global trade. It aspires to be the first choice for customers, employees and investors worldwide. The Group contributes to the world through responsible business practice, corporate citizenship and environmental activities. By the year 2050, Deutsche Post DHL Group aims to achieve zero emissions logistics.
Deutsche Post DHL Group is home to two strong brands: Deutsche Post is Europe’s leading postal service. DHL offers a comprehensive range of international express, freight transport, and supply chain management services as well as e-commerce logistics solutions. Deutsche Post DHL Group employs approximately 570,000 people in over 220 countries and territories worldwide. The Group generated revenues of more than 66 billion Euros in 2020.
THE logistics company for the world.
1
EUR 300 per full-time employee
2
EUR 300 per full-time employee
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005615/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
